{"filing":{"accession_number":"0001062993-26-003545","cik":"0002066836","ticker":"CNXU","company_name":"Conexeu Sciences Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2066836/000106299326003545/form8k.htm"},"events":[{"id":16518,"run_id":14757,"accession_number":"0001062993-26-003545","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Conexeu announced completion of its 12-month preclinical P.R.O.O.F study for its CXU™ tissue-restoration platform, demonstrating successful tissue restoration and injectable performance benchmarks. This is a material operational and development milestone for a preclinical-stage biotech company, signaling progress toward its planned Q1 2027 FDA 510(k) submission in wound care and eventual expansion into the medical aesthetics market. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), this represents a significant operational achievement that would affect a reasonable investor's assessment of the company's development trajectory and commercial prospects.","company_name":"Conexeu Sciences Inc.","ticker":"CNXU","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14643,"accession_number":"0001062993-26-003545","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Conexeu announced completion of its 12-month preclinical P.R.O.O.F study for its CXU™ tissue-restoration platform, demonstrating successful tissue restoration and injectable performance benchmarks. This is a material operational and development milestone for a preclinical-stage biotech company, signaling progress toward its planned Q1 2027 FDA 510(k) submission in wound care and eventual expansion into the medical aesthetics market. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), this represents a significant operational achievement that would affect a reasonable investor's assessment of the company's development trajectory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:13:47.067006+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14643,"accession_number":"0001062993-26-003545","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Conexeu announced completion of its 12-month preclinical P.R.O.O.F study for its CXU™ tissue-restoration platform, demonstrating successful tissue restoration and injectable performance benchmarks. This is a material operational and development milestone for a preclinical-stage biotech company, signaling progress toward its planned Q1 2027 FDA 510(k) submission in wound care and eventual expansion into the medical aesthetics market. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), this represents a significant operational achievement that would affect a reasonable investor's assessment of the company's development trajectory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:13:47.067006+00:00","company_name":"Conexeu Sciences Inc.","ticker":"CNXU","filing_date":"2026-07-07"}]}